Genes including vPS35, FcGr2A, TbcA, HIrA, TYrobP, JUND, PHF20, NFKb2, rPl35A and bIcD2 were considered to play potential roles in the pathology of osteoporosis.
Introduction
osteoporosis, characterised by the impairment of bone microarchitecture and the loss of bone mass and strength, has become an important clinical problem in ageing populations. 1, 2 The spine is the most common site of osteoporotic fractures, followed by the hip, forearm and proximal humerus. 3 osteoporosis is characterised by deterioration of the
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microstructure of bone, specifically at trabecular sites, which leads to pain, deformity, disability and possibly death. 4, 5 A variety of factors contribute to the development of osteoporosis, such as genetic variants, gender, steroid production, age, lifestyle and environment. [6] [7] [8] Additionally, low calcium intake, cigarette-smoking and intake of excessive alcohol may be secondary causes. 4, 9 Generally, osteoporosis is considered a silent disease because it is asymptomatic until a fracture occurs. recently, the treatment of osteoporosis has been mainly pharmaceutical, but treatment may not be satisfactory due to its time-consuming nature and high cost, as well as the side effects of the drugs.
As Sims et al 10 have reported, a number of studies have explored the mechanism of osteoporosis. The members of the Wnt signalling pathway, such as Wnt3a, low-density lipoprotein receptor-related protein 5, secreted frizzled-related protein 1 and sclerostin, have been suggested to be related to variation in bone mineral density (bmD). 10 It is known that osteoporosis is defined clinically by measuring the bmD with heritability estimates of 0.5 to 0. 9. 11 This further demonstrated that bmD is an important clinical marker in osteoporosis. The underlying aetiology of osteoporosis is still not fully understood and the identification of novel therapeutic target genes for osteoporosis is needed.
It is worth mentioning that microarray data analysis is available to identify vital genes and gene regulatory networks associated with disease. 12 In this study, we downloaded the data sets GSe56815 and GSe56814 from the Gene expression omnibus database, and identified the differentially expressed genes (DeGs) in blood samples obtained from osteoporosis patients, followed by Gene ontology (Go) 13 and Kyoto encyclopedia of Genes and Genomes (KeGG) 14 enrichment analyses and interaction network construction between transcription factors (TFs) and DeGs. We aimed to find involvement of key genes in osteoporosis which may be potential modulators in the pathology of osteoporosis.
Methods
Microarray data. The two microarray data sets (https:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSe56815 and https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSe56814) were downloaded using the Geoquery package with r version (The r Foundation for Statistical computing, vienna, Austria) from the Gene expression omnibus (Geo) database. These two microarray data sets were from the blood samples of 67 osteoporosis patients (based on World Health organization (WHo) criteria) and 62 control groups. It is reported that the WHo recommends the use of bmD of the spine and proximal femur measured by double energy X-ray absorption as the benchmark to diagnose osteoporosis and its severity. 15 Therefore, diagnosis of osteoporosis depended on the bmD in these two data sets; these osteoporosis patients all had low bmD. In addition, the patients with osteoporosis did not receive any antiosteoporosis medication or other medication that may affect bone metabolism. Detailed information of two data sets is shown in Table I . Screening of DeGs. Normalised microarray data were downloaded and gene expression value was calculated as the mean value of its corresponding probe values. limma package 17 and meta-mA 18 package were used to identify the DeGs between osteoporosis and control group; p-values and false discovery rates (FDr) were further calculated. FDr < 0.01 was selected as the threshold for screening DeGs. Functional analyses of DeGs. Go and KeGG enrichment analyses were carried out for the identified DeGs using Genecodis3 (http://www.genecodis.cnb.csic.es/ analysis). [19] [20] [21] Significant Go terms and KeGG pathways were identified according to the threshold of p < 0.05. Network construction of DeGs and TFs. To gain deeper insight into the molecular functions of DeGs, the gene regulatory relationships between DeGs and TFs were selected based on human TF binding sites data and genetic coordinate position information, which were available at the UcSc eNcoDe Genome browser. 22 The identified TFs were considered to be associated with DeGs and the regulatory network between DeGs and TFs was visualised using cytoscape software (cytoscape corporation, San Diego, california).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) in vitro. Four women diagnosed with osteoporosis with low bmD were enrolled in this study, as were three women with high bmD but no diagnosis of osteoporosis. The clinical information of osteoporosis patients is shown in Table II . All blood samples were collected for further qrT-Pcr experimentation. All participating individuals provided informed consent with the approval of the ethics committee. Total ribonucleic acid (rNA) of the blood samples was extracted using TrIzol reagent (Invitrogen, carlsbad, california), in accordance with the manufacturer's protocols. Then 1 ug rNA was applied to synthesise DNA by SuperScript III reverse Transcriptase (Invitrogen) and qrT-Pcr was performed in an AbI 7500 real-time Pcr system (Invitrogen) with SYbr Green Pcr master mix (Invitrogen). Glyceraldehyde 3-phosphate dehydrogenase was used as internal Receiver operating characteristic (ROC) analyses. by using the proc package 23 in r language, we performed the roc analyses to assess the diagnostic value of DeGs. The area under the curve (AUc) under the binomial exact confidence interval was calculated and the roc curve was generated.
Results
DeGs identification. In this study, we identified 1320 DeGs with significantly altered expression in osteoporosis blood samples, of which 855 were up-regulated and 465 were down-regulated compared with the control groups. The top 20 (ten up-regulated and ten downregulated) DeGs abbreviations are defined in Table III and presented in FDr, false discovery rate; rNA, ribonucleic acid; mrNA, messenger rNA; ATP, adenosine triphosphate on the other hand, the results of KeGG analysis revealed that a total of 15 pathways were enriched; for example, Ubiquitin mediated proteolysis and osteoclast differentiation (Table vI) .
Transcriptional regulatory relationships between DeGs
and TFs. regulatory relationships were predicted between top 20 DeGs (ten up-regulated and ten down-regulated) and TFs, and the regulatory network was established and visualised by cytoscape software (cytoscape corporation) (Fig. 1) . In this network, there were 6038 interactions pairs involving 88 TFs. The top seven TFs covering the most downstream genes were FoXD3, Nkx2-5, Pax-4, oct-1, HNF-4, Pax-6 and comP1. qRT-PCR. Among the identified DeGs, vPS35, FcGr2A, TbcA, HIrA, TYrobP and JUND were selected to verify the integrated result. The qrT-Pcr results showed that TYrobP and JUND were up-regulated, while vPS35, FcGr2A, TbcA and HIrA were down-regulated. The expression of TbcA, HIrA and TYrobP were consistent with integrated analyses except vPS35, FcGr2A and JUND. The qrT-PcT results are shown in Figure 2 . ROC curve analysis. We performed roc curve analyses and calculated the AUc to assess the discriminatory ability of DeGs (vPS35, HIrA, PHF20 and NFKb2) in data set GSe56815. The AUc of four DeGs including vPS35 (0.789), HIrA (0.77), PHF20 (0.851) and NFKb2 (0.741) was > 0.7 (Fig. 3) . PHF20 had the largest AUc among these four DeGs. For the diagnosis of osteoporosis, the sensitivity (proportion of true positives) and 1-specificity (proportion of false positives) of vPS35 was 52.5% and 92.5%, respectively; the sensitivity and 1-specificity of HIrA was 60% and 87.5%, respectively; the sensitivity and 1-specificity of PHF20 was 77.5% and 85%, respectively; and the sensitivity and 1-specificity of NFKb2 was 67.5% and 75%, respectively.
Discussion
osteoporosis is a complex disease that is characterised by reduced bone mass and the deterioration of bone-tissue microarchitecture, ultimately leading to increased risk of fractures. 24 In the present study, we identified 855 upregulated and 465 down-regulated genes in blood samples of osteoporosis patients compared with control groups. It is well known that osteoclast formation and activation are critical events in maintaining the normal bone mass and structure. Herein, Go and KeGG analyses indicated that these DeGs were significantly involved in osteoclast differentiation, which demonstrated the important role in osteoclast development of osteoporosis. Additionally, the TF-DeGs regulatory network was FDr, false discovery rate; TcA, tricarboxylic acid; trNA, trnaser ribonucleic acid; rNA, ribonucleic acid constructed involving top 20 (ten up-regulated and ten down-regulated) genes and 88 TFs, which further illustrated the role of these DeGs under the regulation of TFs in osteoporosis. Finally, qrT-Pcr in vitro validated the expression patterns of several genes including vPS35, FcGr2A, TbcA, HIrA, TYrobP and JUND. Some results have been inconsistent with the microarray analyses, probably because of the heterogeneity of the studies, including different inclusion criteria and the small number of patients in the validation set. In summary, ten genes including vPS35, FcGr2A, TbcA, HIrA, TYrobP, JUND, PHF20, NFKb2, rPl35A and bIcD2 were considered to play a potential role in the pathology of osteoporosis. It has been reported that vPS35 is highly expressed in osteoclasts as well as osteoblasts and loss of function will increase hyper-resorptive osteoclast formation. 25 Specific vPS35 knockdown in the osteoblast lineage resulted in mildly lowered bone mass in the primary spongiosa. 26 our study found up-regulated expression of vPS35, which indicated that it may function in the regulation of osteoclast and osteoblast activity in osteoporosis. In 
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Relative expression level addition, vPS35 had significant diagnostic value for osteoporosis, which may serve as a diagnostic biomarker of osteoporosis. FcGr2A has been reported to be related to rheumatoid arthritis and is a target gene of drugs in rheumatoid arthritis treatment. 27, 28 It has been indicated that FcGr2A is also associated with ankylosing spondylitis and axial spondyloarthritis. 29 In the current study, we found an increased expression of FcGr2A in osteoporosis, suggesting that FcGr2A may be associated with the pathology of osteoporosis. In human cell lines, TbcA knockdown will decrease a mass of a-and b-tubulin levels, subtle changes in the microtubule cytoskeleton and cell death. 30 Herein, it is down-regulated in osteoporosis blood samples compared with controls. Therefore, we suggest that TbcA may participate in the formation process of cytoskeleton in osteoporosis. HIrA has been recorded associated with H3.3-containing nucleosomes in transcriptional active genomic loci in bone tumours. 31 In this study, we found that HIrA was down-regulated in osteoporosis blood samples, which suggested that HIrA may play a significant role in histone modification in bone development in osteoporosis. In addition, HIrA has diagnostic value for osteoporosis, suggesting that HIrA may be associated with the pathology of osteoporosis and may serve as a diagnostic biomarker of osteoporosis.
TYrobP is a protein involved in osteoclast differentiation and function, such as the generation of the actin cytoskeleton, which is important for bone resorption. 32 In the current study, the expression of TYrobP was The receiver operating characteristic (roc) curves of a) vPS35, b) HIrA, c) PHF20 and d) NFKb2 between osteoporosis patients and healthy controls. The roc curves were used to show the diagnostic ability of these selected differentially expressed genes (DeGs) with 1-specificity (x-axis; the proportion of false positives) and sensitivity (y-axis; the proportion of true positives).
up-regulated, indicating that it may play a vital role in the regulation of osteoclast differentiation in osteoporosis. JUND has proven to control bone formation, osteoblast proliferation, and differentiation. [33] [34] [35] [36] Furthermore, it is a DeG in mesenchymal stem cells in osteoporosis. 37 our results showed that JUND was expressed differentially in osteoporosis, which demonstrated the essential role of JUND in bone formation and osteoporosis. It has been reported that PHF20-null mice show delay in bone formation, defects in skeletal composition and haematopoiesis. 38 We found that PHF20 was up-regulated, suggesting that PHF20 may play a role in bone development through different mechanisms or signal pathways in human osteoporosis. It is noted that PHF20 had a significant diagnostic value for osteoporosis, which may be considered as a biomarker in osteoporosis diagnosis. NFKb2 is reported up-regulated under estrogen treatment in needle bone biopsies of osteoporosis. 39 Additionally, it is a key gene in the TrAIl pathway for osteoporosis fractures. 40 It is noted that bone resorption marker TrAP5b was undetectable in Nfkb2 +/-and Nfkb2 -/-mice, and was slightly but significantly increased by TNF injection in Nfkb2 +/-mice, 41 which suggested the relationship between NFKb2 and bone resorption. moreover, our study revealed that NFKb2 was significantly enriched in osteoblast differentiation, which further indicated that it was an essential molecule in bone metabolism. Additionally, we found that NFKb2 was remarkably associated with diagnosis and may play a valuable role in the clinical and laboratory diagnosis of osteoporosis.
rPl35A participates in cytoplasmic ribosomal protein pathways in osteoarthritis chondrocytes. 42 In addition, it is linked to inherited bone marrow failure syndromes. 43 Herein, we found that rPl35A was down-regulated in osteoporosis blood samples compared with normal controls, which provided another pathogenic role in bone disease. bIcD2 mutation is involved in spinal muscular atrophy. [44] [45] [46] [47] moreover, it has been reported that mutations in bIcD2 will cause early onset non-length dependent lower-limb predominant weakness and contractures. 48 In the present study, we found decreased expression of bIcD2 in osteoporosis, suggesting the vital role in bone formation and metabolism.
There are limitations to our study. First, the sample size in the qrT-Pcr data set was small and larger numbers of blood samples of osteoporosis patients are needed for further research. Secondly, the deregulated DeGs in osteoporosis were identified and the definite biological function was not investigated in our study. In vivo and in vitro experiments are essential for elucidation of the biological roles of DeGs in osteoporosis in future work.
In summary, we identified several key genes including vPS35, FcGr2A, TbcA, HIrA, TYrobP, JUND, PHF20, NFKb2, rPl35A and bIcD2 involved in the regulation of bone formation and metabolism under the regulation of TFs (FoXD3, Nkx2-5, Pax-4, oct-1, HNF-4, Pax-6 and comP1) in osteoporosis. It is noted that vPS35, HIrA, PHF20 and NFKb2 had significant diagnostic value for osteoporosis and may serve as diagnostic biomarkers of osteoporosis. our results may provide important information for studying the pathogenic mechanisms and consequences of osteoporosis.
Supplementary material
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